争吵 发表于 2025-3-23 13:34:07

http://reply.papertrans.cn/3/230/22979/22979-11.png

表示问 发表于 2025-3-23 17:09:52

http://reply.papertrans.cn/3/230/22979/22979-12.png

Ligament 发表于 2025-3-23 20:58:48

http://reply.papertrans.cn/3/230/22979/22979-13.png

方舟 发表于 2025-3-24 01:57:31

Submitted on: 06 May 2023.
Revised on: 26 May 2023.
Accepted on: 03 June 2023.
NEUROPHARMACOLOGY---PERGAMON-ELSEVIER SCIENCE LTD

circumvent 发表于 2025-3-24 05:00:15

http://reply.papertrans.cn/3/230/22979/22979-15.png

让步 发表于 2025-3-24 09:40:07

http://reply.papertrans.cn/3/230/22979/22979-16.png

defendant 发表于 2025-3-24 11:23:47

http://reply.papertrans.cn/3/230/22979/22979-17.png

Enervate 发表于 2025-3-24 17:15:15

http://reply.papertrans.cn/3/230/22979/22979-18.png

groggy 发表于 2025-3-24 21:20:35

Submitted on: 05 January 2001.
Revised on: 09 February 2001.
Accepted on: 19 February 2001.
NEUROPHARMACOLOGY---PERGAMON-ELSEVIER SCIENCE LTD

Malcontent 发表于 2025-3-25 01:33:15

Submitted on: 25 June 2015.
Revised on: 02 August 2015.
Accepted on: 27 August 2015.
NEUROPHARMACOLOGY
页: 1 [2] 3 4
查看完整版本: SCIE期刊NEUROPHARMACOLOGY 2024/2025影响因子:4.678 (NEUROPHARMACOLOGY) (0028-3908). (PHARMACOLOGY & PHARMACY)(药理学与药学)Science C